Nautilus Biotechnology, Inc. (NASDAQ:NAUT) Q1 2024 Earnings Call Transcript

Parag Mallick: Yeah. I think one of the one of the largest as Sergio mentioned, one of the largest changes that we saw was a transition in key opinion leaders and other scientists asking to understand how the platform works, towards a transition towards could I use it for my specific application. And those applications were incredibly wide ranging. They ranged from very detailed mechanistic studies or biological time courses or biomarker studies, but it spanned a wide range of substrates from cell to blood to CSF. And vaccine researchers get into that level of detail of really thinking through, how our platform might apply to the research questions that they’re asking. It should be done beyond understanding, the way that it works. And we’re really excited about how it might expand their proteomic horizons.

Unidentified Analyst: Super. Thank you.

Operator: Thank you. [Operator Instructions] I’m showing no further questions, at this time. This concludes today’s conference call. Thank you for participating. You may now disconnect.